| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 3,290 | 3,230 | 3,090 | 4,140 | 3,870 |
| Sales Growth | +1.86% | +4.53% | -25.36% | +6.98% | +137.42% |
| Net Income | -15,320 | -14,650 | -16,980 | -9,900 | -3,730 |
| Net Income Growth | -4.57% | +13.72% | -71.52% | -165.42% | +18.02% |
Icecure Medical Ltd Ord (ICCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
IceCure Medical Ltd. develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. IceCure Medical Ltd. is based in CAESAREA, Israel.
Fiscal Year End Date: 12/31